Mannheimia haemolytica

Benefit-sharing from DSI rests on the provider country's national framework. Where it requires bilateral benefit-sharing for DSI, those terms apply. Where it gives effect to the CBD multilateral mechanism, users of its publicly available DSI should share benefits through it: all users non-monetary benefits, as appropriate, and commercial users above set size thresholds also monetary contributions to the Cali Fund. Where it is silent on DSI, the position is not yet settled: check with the country's competent national authority, through the ABS service. Any terms agreed when the genetic resources were accessed still apply. Access and benefit-sharing questions are handled by the ABS service, not by the DataBank. Learn more →

Also known as: Pasteurella haemolytica Newsom and Cross 1932 (Approved Lists 1980)

Taxonomic classification

View at source ↗

Related species in the DataBank

Species that share this one's nearest groups in NCBI Taxonomy. This is how they're classified, not a phylogeny. See it in the species tree.

Genome browser

Sequence records

AlphaFold DB proteome: UP000318394 ↗

Proteomics (external sources)

PRIDE — project-level reference (metadata only; no per-protein identifications are available via PRIDE's public API)

Chemical Profiles (external sources)

ChEMBL rows are compounds active against a protein target from this organism — not confirmed as compounds the species itself produces, unlike ANPDB's.

ChEMBL: BINFLOXACIN (View at source ↗) — Target organism (ChEMBL) — not confirmed as a compound this species produces; MED 0.3 mg kg-1AFDSI-METABOLOMICS-2076Copy ID

ChEMBL: CHEMBL157744 (View at source ↗) — Target organism (ChEMBL) — not confirmed as a compound this species produces; MED 0.3 mg kg-1AFDSI-METABOLOMICS-2077Copy ID

ChEMBL: CHEMBL351539 (View at source ↗) — Target organism (ChEMBL) — not confirmed as a compound this species produces; MED 1.2 mg kg-1AFDSI-METABOLOMICS-2078Copy ID

ChEMBL: DANOFLOXACIN (View at source ↗) — Target organism (ChEMBL) — not confirmed as a compound this species produces; MED 0.15 mg kg-1AFDSI-METABOLOMICS-2079Copy ID

ChEMBL: DANOFLOXACIN (View at source ↗) — Target organism (ChEMBL) — not confirmed as a compound this species produces; MED 0.15 mg kg-1AFDSI-METABOLOMICS-2080Copy ID

ChEMBL: PALEIC ACID (View at source ↗) — Target organism (ChEMBL) — not confirmed as a compound this species produces; MIC 0.78 ug.mL-1AFDSI-METABOLOMICS-2081Copy ID

ChEMBL: PALEIC ACID (View at source ↗) — Target organism (ChEMBL) — not confirmed as a compound this species produces; MIC 0.78 ug.mL-1AFDSI-METABOLOMICS-2082Copy ID

Protein Structures

Geographic range (Africa)

5 real GBIF-recorded occurrences across Africa — see this species on GBIF ↗.

This reflects real occurrence records submitted to GBIF, not a comprehensive range map — sampling effort varies significantly by country and region, so an absence here doesn't mean the species isn't present.

ET (3)MA (1)ZA (1)

Derived analysis results

A node's own derived bioinformatics-analysis output (e.g. an SSR/microsatellite discovery archive) run against this species' own genome data — see the Derived Analysis page for the full catalog.

There are more related species. Open the species tree to see them all.